Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 5032Carcinoma, Renal Cell 1579Urinary Bladder Neoplasms 1281Kidney Neoplasms 725Breast Neoplasms 644Neoplasms 633Carcinoma, Transitional Cell 493Carcinoma, Non-Small-Cell Lung 470Neoplasm Metastasis 469Melanoma 423Ovarian Neoplasms 403Colorectal Neoplasms 375Lung Neoplasms 334Pancreatic Neoplasms 263Sarcoma 233Stomach Neoplasms 227Uterine Cervical Neoplasms 226Testicular Neoplasms 216Non-Muscle Invasive Bladder Neoplasms 216Head and Neck Neoplasms 193Squamous Cell Carcinoma of Head and Neck 189Carcinoma, Hepatocellular 170Endometrial Neoplasms 167Colonic Neoplasms 167Esophageal Neoplasms 165Wilms Tumor 159Recurrence 131Triple Negative Breast Neoplasms 130Small Cell Lung Carcinoma 127Neuroblastoma 127

Interventions

danusertib 1cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Metastatic Hormone Refractory Prostate Cancer × Genitourinary × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

NCT00766324 2014-05-28

PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

Nerviano Medical Sciences

Phase 2 Completed
118 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡